SCHEMBL6581932

SCHEMBL6581932

Nc1nccc(-c2cccnc2-c2ccc(F)cc2)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 7/20 0.51
CCNT1 O60563 3/20 0.50
CCNA2 P20248 3/20 0.50
CDK2 P24941 3/20 0.50
CDK9 P50750 3/20 0.50
CSNK1E P49674 3/20 0.50
CDK5 Q00535 2/20 0.50
CDK5R1 Q15078 2/20 0.50
HASPIN Q8TF76 1/20 0.50
FEN1 P39748 2/20 0.49
ADORA1 P30542 1/20 0.48
MAPK13 O15264 2/20 0.47
CSNK1D P48730 2/20 0.47
MAPK12 P53778 2/20 0.47
MAPK11 Q15759 2/20 0.47
EGFR P00533 1/20 0.47
KCNH2 Q12809 1/20 0.47
PRKACA P17612 2/20 0.46
HSP90AA1 P07900 2/20 0.46
AURKA O14965 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15638546 0.81 FEN1 (0.49) MAPK14CCNT1CCNA2CDK2CDK9
SCHEMBL9956071 0.81 ADORA1 (0.64) MAPK14CCNT1CCNA2CDK2CDK9
SCHEMBL28019394 0.79 FEN1 (0.47) MAPK14CCNT1CCNA2CDK2CDK9
SCHEMBL6579207 0.79 MAPK14 (0.53) MAPK14CCNT1CCNA2CDK2CDK9
SCHEMBL17200126 0.79 HSP90AA1 (0.66) MAPK14CCNT1CCNA2CDK2CDK9
SCHEMBL29889857 0.78 CDK5 (0.53) CCNT1CCNA2CDK2CDK9CDK5
SCHEMBL21908761 0.78 CDK5 (0.53) CCNT1CCNA2CDK2CDK9CDK5
SCHEMBL1645470 0.77 CCNT1 (0.53) MAPK14CCNT1CCNA2CDK2CDK9
SCHEMBL30117887 0.77 PTGS2 (0.51) MAPK14CCNA2CDK2CSNK1EFEN1
SCHEMBL15638432 0.77 PTGS2 (0.51) MAPK14CCNA2CDK2CSNK1EFEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1140083-A4 NOVEL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2004-01-02 EP claimed
US-6469018-B1 INHIBITING CYTOKINES AND THE TREATMENT OF A CYTOKINE MEDIATED DISEASE, BY ADMINISTRATION OF COMPOUNDS SUCH AS:2-(4-FLUOROPHENYL)-3-(2-METHYLTHIOPYRIMIDIN-4-YL)PYRIDINE SMITHKLINE BEECHAM CORPORATION 2002-10-22 US claimed
EP-1140083-A1 NOVEL COMPOUNDS SmithKline Beecham Corporation (US) 2001-10-10 EP claimed
WO-2000040243-A1 NOVEL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2000-07-13 WO claimed
EP-1140083-A4 NOVEL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2004-01-02 EP disclosed
US-6469018-B1 INHIBITING CYTOKINES AND THE TREATMENT OF A CYTOKINE MEDIATED DISEASE, BY ADMINISTRATION OF COMPOUNDS SUCH AS:2-(4-FLUOROPHENYL)-3-(2-METHYLTHIOPYRIMIDIN-4-YL)PYRIDINE SMITHKLINE BEECHAM CORPORATION 2002-10-22 US disclosed
EP-1140083-A1 NOVEL COMPOUNDS SmithKline Beecham Corporation (US) 2001-10-10 EP disclosed
WO-2000040243-A1 NOVEL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2000-07-13 WO disclosed